As of 2024-07-27, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -2.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 387.22 mil USD. KPTI's TTM EBITDA according to its financial statements is -132.06 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 21.5x | 16.6x |
| Forward P/E multiples | 17.8x - 24.1x | 21.4x |
| Fair Price | (22.29) - (26.44) | (23.63) |
| Upside | -2396.6% - -2824.3% | -2535.3% |
| Date | EV/EBITDA |
| 2024-07-26 | -2.93 |
| 2024-07-25 | -2.92 |
| 2024-07-24 | -2.91 |
| 2024-07-23 | -2.89 |
| 2024-07-22 | -2.88 |
| 2024-07-19 | -2.86 |
| 2024-07-18 | -2.88 |
| 2024-07-17 | -2.94 |
| 2024-07-16 | -2.96 |
| 2024-07-15 | -2.93 |
| 2024-07-12 | -2.91 |
| 2024-07-11 | -2.92 |
| 2024-07-10 | -2.84 |
| 2024-07-09 | -2.82 |
| 2024-07-08 | -2.77 |
| 2024-07-05 | -2.80 |
| 2024-07-03 | -2.81 |
| 2024-07-02 | -2.78 |
| 2024-07-01 | -2.79 |
| 2024-06-28 | -2.84 |
| 2024-06-27 | -2.93 |
| 2024-06-26 | -2.95 |
| 2024-06-25 | -3.04 |
| 2024-06-24 | -3.05 |
| 2024-06-21 | -2.94 |
| 2024-06-20 | -2.91 |
| 2024-06-18 | -2.90 |
| 2024-06-17 | -2.93 |
| 2024-06-14 | -2.92 |
| 2024-06-13 | -2.98 |
| 2024-06-12 | -2.99 |
| 2024-06-11 | -2.97 |
| 2024-06-10 | -2.93 |
| 2024-06-07 | -2.92 |
| 2024-06-06 | -2.93 |
| 2024-06-05 | -2.95 |
| 2024-06-04 | -2.89 |
| 2024-06-03 | -2.95 |
| 2024-05-31 | -2.93 |
| 2024-05-30 | -2.91 |
| 2024-05-29 | -2.92 |
| 2024-05-28 | -2.95 |
| 2024-05-24 | -3.00 |
| 2024-05-23 | -3.04 |
| 2024-05-22 | -3.06 |
| 2024-05-21 | -3.07 |
| 2024-05-20 | -3.08 |
| 2024-05-17 | -3.09 |
| 2024-05-16 | -3.08 |
| 2024-05-15 | -3.07 |